In a regulatory filing, Cytokinetics (CYTK) president and CEO Robert Blum disclosed the sale of 15,000 common shares of the company on March 31 ...

Cytokinetics, Incorporated has a fifty-two week low of $40.53 and a fifty-two week high of $75.71. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 5.93.

Cytokinetics' President and CEO, Robert I. Blum, expressed confidence in Landry's expertise in financial engineering, capital allocation, and treasury management, which are expected to be ...

Cytokinetics' chief executive Robert Blum said on a conference call that the therapy had a "substantial effect" in the study compared to placebo in obstructive HCM, and seemed to be effective ...

Cytokinetics should hear back from the FDA ... In the company's third-quarter results update, chief executive Robert Blum said that aficamten has a "next-in-class safety and efficacy profile ...

But the biotech stock has since pulled back almost 44% from that point. Cytokinetics Chief Executive Robert Blum called the results of the Sequoia study "pristine." "The consistency and the ...

and our commercial readiness activities are on track to support planned launch activities,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. “During recent months ...

Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive Vice President and Chief Commercial Officer, will participate in a fireside ...

It’s my pleasure to introduce our presenting next presenting company Cytokinetics. On the stage with me, we have Robert Blum, President and Chief Executive Officer. We also have Andrew Callas, EVP, ...

March 03, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq ... Leerink Global Biopharma Conference: Robert I. Blum, President and Chief Executive Officer, and Andrew Callos, Executive ...